Introduction
Uveal melanoma is the most frequent primary intraocular neoplasm in adult humans. Choroidal melanoma is the most common type of uveal melanoma with an annual incidence of six to eight cases per million inhabitants in Western countries. Very few effective therapies are currently available, so the mortality rate is high, with one in two patients dying within 10 years of diagnosis (Pyrhonen, 1998) .
In contrast to cutaneous melanoma, which has been extensively studied, little is known about the molecular pathogenesis of choroidal melanoma. Despite a common embryological origin and similar histological features, cutaneous and choroidal melanoma cells differ in epidemiological and cytogenetic aspects. Moreover, cell cycle deregulation, a hallmark of cancer, is not identical in the cancerous melanocytes of the skin and the choroid. Mouriaux et al. (2000) showed that the main changes affecting the cell cycle machinery in choroidal melanoma concern the cyclin-dependent kinase (cdk) inhibitor, p27 Kip1 . This protein is produced in smaller amounts in choroid tumour cells than in healthy choroid cells. p27
Kip1 has been shown to be under the control of the extracellular signal-regulated kinase (ERK) and phosphatidylinositol 3-kinase (PI3-K) signalling pathways, depending on cell type and stimulus (Wang et al., 2001) . The Ras/ERK signalling pathway, which transmits signals for proliferation, differentiation and survival, is frequently overactivated in cancers (Weinstein-Oppenheimer et al., 2000; Chang and Karin, 2001) . Ras may be activated in response to growth factors and may recruit Raf kinases to the membrane in normal cells. It then initiates a phosphorylation cascade, activating successively the ERK kinases (MEK) 1 and 2, resulting in the activation of ERK1/2. ERK1/2 then phosphorylate and activate cytosolic targets, growth factor receptors, cytoskeleton proteins and nuclear transcription factors such as c-Myc (Gille and Downward, 1999, Peyssonnaux et al., 2000) . A major determinant of the activities of ERK1/2 is the duration and strength of activation of these kinases, as it has been shown that sustained activation of ERK1/2 is required to allow cells to pass the G1 restriction point and to enter the S phase Leevers, 1995, Volmat and Pouyssegur, 2001) .
In cutaneous melanoma, ras genes are commonly mutated. These mutations render Ras oncogenic, resulting in the constitutive activation of diverse downstream signalling pathways, promoting cell proliferation and survival. Mooy and Soparker found no ras mutations in choroidal melanoma, and rejected the hypothesis of a Ras-mediated transformation of choroidal melanocytes (Mooy et al., 1991; Soparker et al., 1993) . We investigated the signalling downstream from Ras in choroidal melanoma cells. We began by studying the roles of Raf-1 and the MEK/ERK module in the regulation of cell proliferation in normal human choroidal melanocytes and in OCM-1 cells. We then investigated the link between the Raf-1 and MEK/ERK signalling that controls cell proliferation and cell cycle regulators such as p27
Kip1 and c-Myc.
Materials and methods

Cell cultures and treatments
Normal choroidal melanocytes (NCM) were isolated from postmortem human enucleated eyes (generously provided by Dr C-A Maurage, CHRU Lille, France and Professor P Gain, Faculte´de Me´decine, Saint-Etienne, France), as previously described (Hu et al., 1993) . NCM were cultured in FIC medium: F12 Ham's medium supplemented with 20% foetal calf serum (FCS), 2.5 mg/ml fungizone/amphotericin B, 50 mg/ ml gentamycin, 2 mM L-glutamine (GibcoBRL/InVitrogen, Cergy-Pontoise, France), 10 ng/ml cholera toxin (Calbiochem, Meudon, France), 0.1 mM isobutyl methylxanthin (IBMX) (Sigma, Saint-Quentin Fallavier, France), and 10 ng/ml FGF2 (obtained from Dr H Prats, INSERM U397, Toulouse, France). OCM-1 (ocular choroidal melanoma-1) cells were grown in RPMI 1640 medium supplemented with 5% FCS, 2.5 mg/ml fungizone/amphotericin B, 50 mg/ml gentamycin, and 2 mM L-glutamine (Gibco/BRL, InVitrogen, Cergy-Pontoise, France) (Kan-Mitchell et al., 1989) . Both NCM and OCM-1 cells were cultured at 371C in a humidified air/CO 2 (19 : 1) atmosphere. The proliferative effects of FCS, IBMX plus CT, and FGF2 on NCM were studied in FCS-, IBMX plus CT-and FGF2-depleted cell cultures, respectively. In some experiments, molecular aspects of cell proliferation were investigated by treating cells with specific pharmacological inhibitors of signalling pathways. Stock solutions were made by diluting each inhibitor in dimethyl sulphoxide (DMSO) such that the final concentration of DMSO in culture media did not exceed 0.1%, a concentration that has no effect on the proliferation of NCM and OCM-1 cells. Cells were seeded in triplicate on 12-well plates at a density of 100 000 cells/well for NCM and 50 000 cells/well for OCM-1 cells. The plates were incubated for 3 days. Inhibitors of Raf-1 (Raf-1 kinase inhibitor I) and MEK1/2 (PD98059) (Calbiochem, Meudon, France), were added 12 h before the induction of cell proliferation, on the first day of stimulation and on day 3 of the cell proliferation assay. The number of viable cells was determined by the MTT (3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) colorimetric method as previously described (Mosmann, 1983) . Percentage growth inhibition was calculated by comparison with the growth of control DMSOtreated cells.
Western blot analysis
Cell proliferation was stimulated and NCM and OCM-1 cells were then washed twice in PBS, lysed in ice-cold lysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 0.1% NP-40, 1% deoxycholate, 50 mM b-glycerophosphate, 0.2 mM sodium orthovanadate, 50 mM sodium fluoride, 1 mg/ml leupeptin, 5 mM pepstatin, 20 TIU/ml aprotinin, 1 mM PMSF) and centrifuged at 41C for 10 min at 10 000 g. Protein concentrations were determined with the Bio-Rad protein assay reagent according to the Bradford method. Cell lysates were mixed with 3 Â Laemmli buffer and heated for 5 min at 951C. They were then resolved by SDS-PAGE (12-15% polyacrylamide gel), transferred onto PVDF membrane (Immobilon TM , Millipore, Bedford, USA) by electroblotting and probed with a monoclonal anti-p27
Kip1 antibody (dilution 1 : 100, Santa Cruz, USA), or polyclonal antibodies directed against Raf-1, c-Myc (dilution 1 : 200, Santa Cruz, USA), MEK1/2 (dilution 1 : 1000, Cell Signaling Technology, MA, USA), ERK1, ERK2 (dilution 1 : 1000, BD PharMingen, Erembodegem, Belgium) to determine the amounts of these kinases in the cells throughout the assay. Polyclonal antibodies directed against phospho-Raf-1 (ser /ser 62 ) (dilution 1 : 1000, Cell Signaling Technology, MA, USA) were used to analyse the activation of these kinases during the proliferation of NCM and OCM-1 cells. Polyclonal antibody directed against b-actin (dilution 1 : 500, Santa Cruz, USA) was used as an internal standard for checking protein loading and antisense oligonucleotide specificity. These primary antibodies were tagged with a secondary horseradish peroxidase-conjugated goat antirabbit antibody and the resulting antibody complexes were detected by enhanced chemiluminescence (ECL) (Amersham, Orsay, France). The membrane was placed against BioMax Light-1 film (Kodak, France).
Oligonucleotide treatment of the cells
Phosphorothioate sense and antisense oligonucleotides (ODNs) directed against ERK2 were designed from the published sequence of the murine erk2 gene; they targeted the translation initiation codons of the ERK1 and ERK2 mRNAs (Her et al., 1991) . The targeted sequence was identical in ERK1 and ERK2, and was conserved in humans, mice and rats. The antisense-ODN sequence was 5 0 -GCC-GCC-GCC-GCC-GCC-AT-3 0 (referred to as AS ERK2) and the corresponding sense-ODN sequence was 5 0 -ATG-GCG-GCG-GCG-GCG-GC-3 0 (referred to as S ERK2). Mismatched and antisense phosphorothioate ODNs directed against Raf-1 were designed from the published sequence of the human raf-1 gene and targeted the 3 0 untranslated region of the Raf-1 mRNA, a sequence conserved in humans, mice and rats (Monia et al., 1996) . The antisense-ODN sequence was 5 0 -TCC-CGC-CTG-TGA-CAT-GCA-TT-3 0 (referred to as AS Raf-1) and the control was an analogue of AS Raf-1 ODN with a seven-base mismatch in the middle of the sequence: 5 0 -TCC-CGC-GCA-CTT-GAT-GCA-TT-3 0 (referred to as Mis Raf-1). We used the Lipofectin s reagent (Gibco BRL, InVitrogen, Cergy Pontoise, France), a polycationic lipid, to deliver the ODNs, as this method enhanced ODN uptake and stability in the cell. All ODNs were synthesized commercially (Life Technology, In Vitrogen, France) and purified by HPLC. Experiments were performed with 1 mM ODN and 7.5 mg/ml lipofectin. OCM-1 cells were cultured for 3 days in medium containing 5% heatinactivated FCS. They were then transfected with ODNs/ lipofectin for 4 h, washed twice with serum-free medium and cultured in fresh antibiotic-free growth medium supplemented with 1 mM ODNs without lipofectin for 6 days.
Statistics
Two-tailed Student's t-tests (normal distributions with equal variances) and Mann and Whitney tests (nonparametric tests) were used for statistical analysis.
Results
Higher levels of cell proliferation and differential activation of the Raf-1/MEK/ERK signalling pathway in OCM-1 choroidal melanoma cells NCM grew slowly, with a doubling time of approximately 72 h (Figure 1a ). The depletion of FGF2, cAMP or FCS from culture medium inhibited NCM cell proliferation (Figure 1b) , suggesting that multiple signalling pathways were responsible for the intracellular signal transduction required for this process. Conversely, human choroidal melanoma cells of the OCM-1 cell line grew rapidly in medium supplemented only with 5% FCS, with a doubling time of 18-24 h ( Figure 1a ). OCM-1 cells proliferated even in the presence of low concentrations (0.5%) of FCS. Treatment with a combination of 20% FCS plus FGF2 plus cAMP-increasing agents (FIC medium) did not affect the kinetics of OCM-1 cell proliferation ( Figure 1c ). These data suggest that either FCS alone was sufficient to activate the various signalling pathways necessary for OCM-1 cell proliferation, or some of these signalling pathways were constitutively activated in melanoma cells.
We investigated whether the MAPK pathway was involved in the control of cell growth in NCM and OCM-1 cells by studying the phosphorylation/activation levels of MEK1/2 and ERK1/2 after stimulating cell proliferation ( Figure 2 ). The phosphorylation status of MEK and ERK was investigated by Western blot analysis, using two antibodies that specifically recognize active MEK1/2 and ERK1/2, respectively. Surprisingly, MEK1/2 phosphorylation was barely detectable over the first 2 h of stimulation of NCM, although MEK1/2 were produced at stable levels over this period (Figure 2a) . After 6 h of stimulation of NCM proliferation, MEK1/2 activation increased until 24 h. In contrast, MEK1/2 were strongly activated in OCM-1 cells, even before cell stimulation ( Figure 2a ). MEK1/2 phosphorylation levels remained high over the 24-h period of culture. Over these 24 h of culture, MEK1/2 production levels were constant in both NCM and OCM-1 cell cultures (Figure 2a ). ERK1 and ERK2 were also differentially activated in NCM and OCM-1 cells. In NCM, ERK1 phosphorylation was barely detectable over the first 2 h of stimulation and then increased over the 24-h period of stimulation ( Figure 2b ). Weak levels of ERK1 production were detected over the 24-h period of culture ( Figure 2b ). As for ERK1 phosphorylation, only weak basal levels of phosphorylated ERK2 were detected over the first 2 h of stimulation with an increase over the 24-h period of stimulation. We thought that, as for ERK1, the low levels of detection of ERK2 phosphorylation might result from low levels of ERK2 production in NCM, but ERK2 production analysis invalidated this hypothesis (Figure 2b ). The phosphor- NCM and OCM-1 cells were seeded at a density of 50 000 cells/well in 12-well plates and cultured for 6 days in their respective complete media. (b) Effects of FGF2, FCS and cAMP-increasing agents on NCM proliferation. Cells were seeded in FIC medium for 3 days and then cultured in FIC medium without FCS (serum-depleted medium), FIC medium without IBMX þ CT (depletion of cAMPincreasing agents), and FIC medium without FGF2 (depletion of FGF2) over a 6-day period. NCM proliferation was compared with that of OCM-1 cultured in complete media. (c) Dose-dependent effect of FCS on OCM-1 cell proliferation. Cells were cultured in 5% FCS culture medium for 3 days, then in the presence of various concentrations of serum and their proliferation was compared with that of NCM cultured in FIC medium. (a-c) Cell proliferation was determined by MTT colorimetric assay. Similar results were obtained in four independent experiments ylation kinetics of both ERK1 and ERK2 perfectly matched those of MEK1/2 in OCM-1 cells. High basal levels of ERK1/2 phosphorylation were detected before serum stimulation (Figure 2b ). ERK1/2 phosphorylation levels increased after serum stimulation and remained high over the 24-h period of culture (Figure 2b ). During the culture period, ERK1/2 production levels were constant in OCM-1 cell cultures (Figure 2b ).
These data show that the MEK/ERK module is activated late in NCM cells, whereas it is constitutively activated in OCM-1 cells.
Activation of the MEK/ERK module plays a specific key role in the proliferation of OCM-1 cells
We investigated whether constitutive activation of the MEK/ERK module was involved in OCM-1 cell proliferation by treating both NCM and OCM-1 cells with the pharmacological inhibitor, PD98059. This product specifically prevents the activation of ERK1/2 by binding to and inhibiting MEK1, and has been used to demonstrate the role of ERK1/2 in the proliferation of various cell types (Alessi et al., 1995) . NCM proliferation was reduced by only 8-13% in cells cultured for 6 days in the presence of PD98059 at concentrations of 5-20 mM, with control cells used as the reference (vehicle-treated or nontreated cells) (Figure 3a) . In contrast, OCM-1 cell treatment with PD98059 reduced cell proliferation in a dose-dependent manner ( Figure 3a) . The maximal inhibitory effect on cell proliferation was observed with 20 mM PD98059 (cell number decreased by 67% on day 6 of culture) (Figure 3a) . These data clearly show that MEK1 activation is a key, specific step of the signalling promoting OCM-1 cell proliferation. To confirm that PD98059 inhibited OCM-1 cell proliferation by inhibiting the activation of ERK1/2, we investigated the phosphorylation states of MEK1/2 and ERK1/2 by Western blotting. In vehicle-treated cells, MEK1/2 activation was sustained over the 6-h culture period, whereas OCM-1 cell treatment with PD98059 rapidly reduced MEK1/2 activation (Figure 3b ). However, PD98059 did not affect MEK1/2 production levels. Similarly, ERK1/2 activation was sustained over the 6-h culture period in vehicle-treated OCM-1 cells, whereas treatment with PD98059 rapidly and completely abolished ERK1/2 activation (Figure 3b ). The inhibitory effects of PD98059 on ERK1/2 phosphorylation were not mediated by the inhibition of ERK2 production (Figure 3b ). These data demonstrate that MEK1 is key component of the signalling pathway mediating OCM-1 cell proliferation, whereas it is involved only in a small extent in proliferative signal transduction in NCM.
We investigated whether ERK1/2 played a role in the control of OCM-1 cell proliferation, by depleting ERK1/2 from cell cultures, using an antisense (AS) oligonucleotide (ODN) strategy. The treatment of OCM-1 cells with AS ERK1/2 specifically blocked Figure 2 Comparison of the production and activation of MEK1/2 and ERK1/2 during the proliferation of NCM and OCM-1 cells. OCM-1 cells and NCM were cultured for 3 days in their respective complete growth medium and were then cultured in serum-depleted and serum-, FGF2-and IBMX/CT-depleted culture medium, respectively for 12 h. NCM and OCM-1 cells were then stimulated with FIC medium and RPMI supplemented with 5% FCS, respectively, and lysed at the indicated times. Protein (30 mg) was reduced and subjected to SDS-PAGE and Western blotting with specific antiphospho-MEK1/2 and anti-MEK1/2 (a), and specific antiphospho-ERK1/2 anti-ERK1 and anti-ERK2 antibodies (b), as described in Materials and methods. Similar results were obtained in four independent experiments
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Kip1 and c-Myc in OCM-1 cells G Lefevre et al ERK1 production and greatly reduced ERK1/2 production (by up to 70%). Levels of ERK1, ERK2 and bactin production were unaffected in nontransfected and S ERK-transfected OCM-1 cells (Figure 4a ), demonstrating that AS ERK depleted ERK1/2 specifically. The decrease in ERK1/2 production caused by the AS ERK in OCM-1 cells resulted in a 55% reduction in cell proliferation with respect to lipofectin-treated and S ERK-transfected OCM-1 cells (Figure 4b ). These data confirmed that ERK1/2 play a key role in OCM-1 cell proliferation and demonstrate that the MEK/ERK module is part of the major signalling pathway involved in the control of OCM-1 cell proliferation.
Does Raf-1 control the proliferation of OCM-1 cells?
We investigated the possible activators of the MEK/ ERK signalling pathway. The protein best known for its role in phosphorylating and activating MEK1/2 is the serine/threonine kinase Raf-1. We investigated whether Raf-1 played a role in the control of OCM-1 cell proliferation by inhibiting this molecule via two complementary strategies ( Figure 5 ). First, we treated NCM and OCM-1 cells with a pharmacological inhibitor of Raf-1 -the Raf-1 kinase inhibitor I -to prevent specifically Raf-1 activation (Figure 5c ). The dose-dependent effect of this inhibitor of Raf-1 kinase activity on cell proliferation was analysed over a 6-day period of culture. Raf-1 inhibition did not significantly affect the proliferation of NCM (11-16% of inhibition) (Figure 5a ). In striking contrast, the treatment of OCM-1 cells with 10 and 25 mM Raf-1 kinase inhibitor I resulted in 68 and 89% decrease in cell proliferation, respectively, after 6 days of culture (Figure 5a ). This suggests that the activation of Raf-1 played a key role in the proliferation of OCM-1 cells but not in that of NCM. To confirm this, we depleted Raf-1 from cells by an AS ODN approach. Treatment with Raf-1 AS specifically inhibited Raf-1 production over the 6-day period of culture (data not shown) and induced a 69% (Figure 5b) , demonstrating the specificity of the effect of Raf-1 depletion on OCM-1 cell proliferation. We investigated whether Raf-1 controlled OCM-1 cell proliferation through activation of the MEK/ERK module by treating OCM-1 cells with Raf-1 kinase inhibitor I (25 mM) and analysing the activation states of MEK1/2 and ERK1/2 by Western blotting over a 48-h period. We showed that the decrease in cell proliferation observed after treatment with the Raf-1 kinase inhibitor was correlated with a decrease in Raf-1 activation (Figure 5c ). The large increase in Raf-1 phosphorylation observed in untreated OCM-1 cells after 24 and 48 h of culture was reduced at these times by 70 and 100%, respectively, by Raf-1 kinase inhibitor I treatment (Figure 5c ). This decrease in Raf-1 phosphorylation induced a complete blockade of the activation of MEK1/2 and ERK1/2, without affecting the levels of production of Raf-1, MEK1/2 and ERK2 (Figure 5c ), demonstrating that Raf-1 is a major activator of the MEK/ERK module in OCM-1 cells.
In conclusion, these data demonstrate that Raf-1 and the MEK/ERK signalling pathway strictly control OCM-1 cell proliferation, but not NCM proliferation. Cell proliferation is thus mediated by different signalling pathways in NCM and OCM-1 cells.
Establishment of a direct link between activation of Raf-1, the MEK/ERK module and cell cycle regulators in the control of OCM-1 proliferation
The molecular events downstream from Raf-1 and the MEK/ERK module required to promote cell cycle entry may be cell type-and cell state-specific. The Raf/MEK/ ERK signalling pathway controls cell proliferation in part by modulating the transcription of genes encoding proteins involved in regulation of the cell cycle (Wilkinson and Millar, 2000) . To study the downstream molecular events emanating from Raf-1 and the MEK/ ERK module, we first compared the levels of production of the CDK inhibitor, p27
Kip1 in NCM and OCM-1 cells. We then investigated the effects of inhibiting the activation of Raf-1 and the MEK/ERK module on the levels of production of p27 Kip1 in OCM-1 cells.
Marked underproduction of p27
Kip1 in choroidal melanoma cells and an inverse correlation between the number of mitotic figures and p27
Kip1 production in choroidal melanoma have been reported (Mouriaux et al., 1998) . Western blotting showed that p27 Kip1 production levels were high and constant over the 48-h period of culture in NCM, whereas they were very low in OCM-1 cells over the same period (Figure 6a ). These data suggest that p27
Kip1 production may be negatively regulated in OCM-1 cells. We therefore thought that the MEK/ERK pathway might control p27
Kip1 production. We cultured OCM-1 cells in the presence or absence of PD98059 for 48 h to prevent ERK1/2 activation. Levels of p27
Kip1 remained constant and were not modified by PD98059 treatment of OCM-1 cells, during the first 6 h of culture (Figure 6b) . Thereafter, the inhibition of ERK1/2 activation induced a large increase in the production of p27
Kip1 over the 48-h period of culture, suggesting that MEK/ERK inhibition has a late effect on the production of this compound. We also investigated the role of Raf-1 in the control of p27 Kip1 production by treating OCM-1 cells with Raf-1 inhibitor Figure 5 Effects of the inhibition of Raf-1 activation and Raf-1 depletion on cell proliferation and Raf-1/MEK/ERK pathway activation. NCM and OCM-1 cells were cultured for 3 days then treated with the Raf-1 inhibitor-Raf-1 kinase inhibitor I and cell proliferation was determined by MTT colorimetric assay (a), the production and activation of Raf-1, MEK1/2 and ERK1/2 were analysed by Western blotting (c). OCM-1 cells were cultured in complete medium for 24 h and were then transfected with lipofectin alone, lipofectin plus Mis Raf-1 or AS Raf-1 in serum-free medium for 4 h, as described in Materials and methods (b). OCM-1 cell proliferation was determined after a 6-day period of culture, by MTT colorimetric assay. Similar results were obtained in three independent experiments
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Kip1 and c-Myc in OCM-1 cells G Lefevre et al I for 48 h and analysing p27 Kip1 production levels after 6, 24 and 48 h. As observed with MEK/ERK inhibition, p27
Kip1 production levels were unaffected for the first 6 h of Raf-1 inhibition and then increased substantially until the end of culture period (Figure 6c ). Thus, both Raf-1 and the MEK/ERK module negatively control p27 Kip1 production in OCM-1 cells, over long periods of time.
Amplification of c-Myc was recently detected in choroidal melanoma (Parrella et al., 2001) . The increase in c-Myc protein observed as cells enter G1 phase reflects both an increase in transcription of the c-Myc gene and protein stabilization. Transcriptional activity is controlled by phosphorylation of the Thr 58 and Ser 62 residues of c-Myc (Gupta et al., 1993) . We used Western blotting to investigate c-Myc production and phosphorylation, using both anti-c-Myc and antiphosphorylated c-Myc (thr 58 /ser 62 ) antibodies. We found that c-Myc was differentially produced in the two types of melanocyte (Figure 7) . In contrast to proliferating NCM, in which almost no c-Myc was detectable, proliferating OCM-1 cells produced large amounts of c-Myc over the 24-h period of culture (Figure 7a ). This suggested that the overproduction of c-Myc might result from the persistent, high level of activation of the Raf-1 signalling pathway in OCM-1 cells. We treated OCM-1 cells with 25 mM Raf-1 inhibitor I for 48 h. The production of c-Myc was not affected in OCM-1 cells after 24 h of treatment (Figure 7b ). However, production levels of cMyc were lower in Raf-1 inhibitor-treated OCM1 cells than in untreated cells after 48-h (Figure 7b ). MEK/ ERK inhibition with PD98059 also induced a large decrease in levels of c-Myc production after 48 h of culture (Figure 7b ). These data demonstrate that c-Myc production is positively controlled by Raf-1 and the MEK/ERK module over a long period of time, but with an initial time lag. We then investigated c-Myc transcriptional activity in NCM and OCM-1 cells (using antiphosphorylated c-Myc (Thr 58 /Ser 62 ) antibody), and the role played by Raf-1 in this transcriptional activity in OCM-1 cells. No transcriptional activity was found in NCM as no phosphorylated c-Myc was decteted. In contrast, an increase in the level of c-Myc phosphorylation was detected after 10 min of culture in OCM-1 cells (Figure 7c ). We thought that Raf-1 might control the transcriptional activity of c-Myc in OCM-1 cells. We therefore cultured OCM-1 cells in the presence or absence of 25 mM Raf-1 inhibitor I. The inhibition of Raf-1 completely abolished c-Myc phosphorylation 10 min after treatment with the inhibitor (Figure 7d ), suggesting that Raf-1 rapidly exerts positive control over c-Myc activation, whereas its positive effects on c-Myc production are delayed. The phosphorylation of c-Myc was rapidly reduced by MEK/ERK inhibition in OCM-1 (Figure 7c ), strongly suggesting that the MEK/ ERK module also positively controls the transcriptional activity of c-Myc in OCM-1 cells.
In conclusion, these data demonstrate that there is a direct link between the Raf-1/MEK/ERK signalling cascade and a component of the cell cycle machinery, p27
Kip1 and between this cascade and the production and activation of the transcription factor, c-Myc.
Discussion
Production levels, and the duration and strength of MEK/ ERK pathway activation are determinants for the control of cell proliferation in OCM-1 cells Activation of the MAP kinases, ERK1 and ERK2, is required for the transduction of a wide range of cellular activities including cell proliferation, differentiation, survival and migration. ERK1/2 are key mediators in signal transduction from the cell surface to the nucleus. The duration of ERK activation is critical for cell signalling decisions (Volmat and Pouyssegur, 2001 ). Mitogen-stimulated ERK1/2 activation is generally strong but transient in normal, nontransformed cells. In this study, we showed that MEK1/2 and ERK1/2 were strongly activated, even in the absence of serum stimulation, in the choroidal melanoma cell line, OCM-1. In contrast, the MEK/ERK module was not activated in unstimulated, normal choroidal melanocytes. MEK/ ERK activation occurred only at a later stage of stimulation in NCM, whereas persistent activation was observed in OCM-1 cells, suggesting differences in the downstream targets of this module in normal and 
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Kip1 and c-Myc in OCM-1 cells G Lefevre et al tumoral choroidal melanocytes. We also demonstrated that ERK1/2 activation was necessary for OCM-1 cell proliferation, but not for NCM cell proliferation. This strongly suggests that the ERK1/2 signalling pathway plays a key role in the transmission of extracellular mitogenic signals to the intracellular cell cycle machinery in choroidal melanoma cells. Constitutive activation of both ERK1 and ERK2 has been observed in a large number of tumours and transformed cell lines, and has been shown to be related to cell proliferation (Weinstein-Oppenheimer et al., 2000) . A direct relationship between the duration and magnitude of ERK activation and cell migration has been observed in human breast cancer cells (Krueger et al., 2001) . In contrast, sustained activation of ERK1/2 has been shown to be linked to paclitaxel treatment and apoptosis in neuroblastoma cells and to gonadotropin-releasing hormone agonistinduced antiproliferative effects on ovarian cancer cells (Kimura et al., 1999; Guise et al., 2001) . These data suggest that sustained activation of the ERK pathway may mediate different, and in some cases opposite, biological activities in tumour cells, depending on the origin of those cells. They also strongly suggest that specific inhibition of ERK activation may not occur in all forms of cancer. The precise cause of the constitutive activation of ERK1/2 in many tumour cells remains unclear. It has been shown that overactivation of ERK1/2 results from an increase in the levels of production of both ERK1 and ERK2 in breast cancers (Sivaraman et al., 1997) .
Similar amounts of ERK2 were produced in NCM and OCM-1 cells, suggesting that the specific activation of the ERK2 pathway in OCM-1 cells does not simply reflect an increase in ERK2 production. In contrast, ERK1 was barely detectable in NCM, whereas it was strongly detected in OCM-1 cells. These data suggest that the activation and proliferation of melanoma cells may be due to the overproduction of ERK1. However, ERK1 has not yet been demonstrated to be involved in cancer and no deregulation in cell proliferation has been observed in erk1 À/À mice, demonstrating that most ERK1 functions may be performed by ERK2 (Pages et al., 1999) . It was recently demonstrated that sustained and constitutive ERK activation could be controlled by MEK-independent pathways in normal and tumour cells (Barry et al., 2001 ). This does not seem to be the case in OCM-1 cells. Although, the kinetics of activation of the MEK/ERK module differed in OCM-1 cells and NCM, a strict correlation was observed between MEK activation and subsequent ERK activation in both tumoral and normal cells. This suggests that there is a parallel between the late activation of MEK/ERK and low levels of cell proliferation in normal melanocytes, and between persistent MEK/ERK activation and rapid cell proliferation in transformed melanocytes. However, there is no clear rule governing the correlation between MEK and ERK production in normal and tumoral cells.
The Ras/Raf/MEK/ERK pathway has been described as a linear cascade involved in the control of proliferation in normal cells. Sustained activation of the MEK/ ERK module is frequently, but not always, associated with Raf-1 activation in a large number of human tumours (Weinstein-Oppenheimer et al., 2000) . It was recently shown that mutation in the B-Raf gene induces the constitutive activation of ERK1/2 in various tumours (Davies et al., 2002) . It would be of interest to investigate mutations in B-Raf in choroidal melanomas. We demonstrated, by means of pharmacological and antisense ODN strategies, that Raf-1, like MEK/ ERK, is necessary for the transmission of signals for OCM-1 cell proliferation. However, our data do not exclude the possibility that there is a parallel signalling pathway involving B-Raf for the control of choroidal melanoma cell proliferation. In contrast, Raf-1 inhibition had few effects on NCM proliferation, confirming that the Raf-1/MEK/ERK module is not involved in NCM proliferation.
Role of the downstream targets of the persistently activated ERK pathway in OCM-1 cells
The transcriptional activation of immediate-early genes mediated by the Raf/MEK/ERK pathway may diverge at the level of ERK. Overexpression of the erk1 cDNA results in activation of the transcription factor Elk-1. In contrast, overexpression of the erk2 cDNA activates the transcription of c-myc but not of elk-1 (Chuang and Ng, 1994). Both transcription factors, Elk-1 and c-Myc, are involved in the regulation of cell proliferation and the deregulation of c-myc expression is a common feature of many cancers (Jamerson et al., 2000) . We therefore suggest that signalling pathways downstream from both ERK1 and 2 are required for the high rate of cell proliferation observed in tumoral choroidal melanocytes. Both c-Myc and Elk-1 (unpublished data) are under the control of ERK1/2 in OCM-1 cells, suggesting that they may be necessary for the induction of cell proliferation. C-Myc has been shown to be important in cutaneous melanoma, as its downregulation induces G1 arrest and activates apoptosis (D'Agnano et al., 2001) . In addition, c-Myc amplification was recently detected in 30% of primary uveal melanomas (Parrella et al., 2001) , suggesting that both genetic changes and signalling deregulation are involved in the increased in c-Myc production of in choroidal melanoma cells.
Progression through the cell cycle involves the sequential activation and inhibition of cyclin-dependent kinases (cdks). The activity of cdks is regulated by the binding of these proteins to cyclins and cdk-cyclin complexes are inhibited by cdk inhibitors such as p27 Kip1 . p27
Kip1 accumulates in response to antiproliferative stimuli. The stimulation of quiescent cells by mitogens leads to p27 Kip1 downregulation, which is required for the G 1 /S transition and is associated with tumour progression (Coats et al., 1996) . We demonstrated that p27
Kip1 was produced in large amounts in NCM cultures, whereas it was produced in only very small amounts in OCM-1 cells. These results confirm those of Mouriaux et al. (1998) , showing a striking underproduction of p27 Kip1 in three choroidal melanoma cell lines including OCM-1 cells. Inhibition of Raf-1 and the MEK/ERK module increased p27
Kip1 production, suggesting that this pathway may be involved in the degradation of p27 Kip1 . This hypothesis is supported by data showing that ERK1 phosphorylates p27
Kip1 and targets it to the ubiquitin-proteasome pathway for degradation (Coats et al., 1996) . ERK-controlled p27 Kip1 production has recently been demonstrated in various tumour cells, showing that this phenomenon is not restricted to melanoma (Hoshino et al., 2001) . These data contrast with data showing that the inhibition of PI 3-K leads to the upregulation of p27
Kip1 production in OCM-1 cells . This apparently conflicting result may be accounted for the possible control of ERK activation by the PI3-K signalling pathway. It would therefore be of interest to study the role of PI3-K signalling in the control of p27 Kip1 production, in control of ERK1/2 activation and in regulation of the proliferation of NCM and OCM-1 cells. Finally, our study showed that the activation of cMyc was rapidly controlled by the Raf-1/MEK/ERK pathway. Our data suggest that control of c-Myc by the Raf-1/MEK/ERK signalling pathway operates at transcriptional and protein levels in OCM-1 cells. It has been demonstrated that c-Myc upregulates p27
Kip1 production in cutaneous melanoma cells (D'Agnano et al., 2001 ). Levels of c-Myc and p27
Kip1 were inversely correlated in both NCM and OCM-1 cells, suggesting that c-Myc and p27
Kip1 may display opposite patterns of regulation in normal and melanoma cells.
In conclusion, our study provides the first evidence for a connection between Raf-1, the MEK/ERK module, a key component of the cell cycle machinery, p27 Kip , and the transcription factor c-Myc in control of the proliferation of human choroidal melanoma cells. Furthermore, the molecular mechanisms involved in the control of cell proliferation appeared to differ between human choroidal and cutaneous melanoma cells. The demonstration that Ras mutation-independent activation of both Raf-1 and the MEK/ERK module are specifically involved in the proliferation of choroidal melanoma cells and not in the proliferation of normal choroidal melanocytes may have important implications for the development of more selective methods for the treatment of choroidal melanoma.
